DATROWAY® (datopotamab deruxtecan-dlnk) granted Priority Review in the US as 1st-line treatment for patients with ...
WILMINGTON, Del.--(BUSINESS WIRE)--Feb 3, 2026-- AstraZeneca and Daiichi Sankyo’s supplemental Biologics License Application (sBLA) for DATROWAY ® (datopotamab deruxtecan-dlnk) has been accepted and granted Priority Review in the US for the treatment of …